Search Results
Mar 27, 2026, 10:33 ET India Water Pump Market to Reach USD 4.56 Billion by 2032, Driven by Expanding Water Infrastructure and Agricultural Demand | Vyansa Intelligence
holding a significant share, indicating a moderately consolidated competitive landscape.Leading companies in the India water pump market include ITT, IDEX, Dover, Flowserve, Sulzer AG, KSB, Xylem, Grundfos, Ebara, and SPX Flow, among others.Rising Infrastructure Investments
More news about: Vyansa Intelligence
Mar 19, 2026, 03:33 ET Industrial Water & Wastewater Pump Market Worldwide to Reach USD 5.71 Billion by 2032, Driven by Expanding Wastewater Treatment Infrastructure | Vyansa Intelligence
market share, indicating a moderately consolidated competitive environment.Leading companies operating in the global market include WILO, Ebara, ITT Goulds Pumps, Grundfos, Flowserve, among others.Key Demand Drivers Supporting the Expansion of the Global Industrial Water
More news about: Vyansa Intelligence
Mar 16, 2026, 08:00 ET Over 1,400 High School Scholars Earn National Honors for Performance in Top College Courses
Public SchoolsAlcott College Prep High School, Principal MoodyKing College Prep, Principal KellyPerspectives/ITT Math & Science Academy, Principal BanksThornton Fractional District 215Thornton Fractional South High School,
More news about: National Education Opportunity Network
Mar 08, 2026, 23:54 ET PEI-Genesisが東京で開催されるスマートエネルギーWeekに出展
化用途向けの最新相互接続イノベーションをご覧いただけます。スマートエネルギーWeekにおいてPEI-Genesis は、EV充電、エネルギー貯蔵システム、電化、産業オートメーションなど、次世代エネルギーシステムを支えるために設計された高出力相互接続ソリューションおよびカスタムケーブルアセンブリの幅広い製品ポートフォリオを展示します。主なサプライヤーパートナーには、Amphenol、ITT Cannon、Positronicなどが含まれています。
More news about: PEI-Genesis
Feb 24, 2026, 04:33 ET Centrifugal Pumps Market to Reach USD 55.4 Billion by 2035 as Water Infrastructure Upgrades and Smart Pumping Technologies Drive Global Demand
including Ebara Corporation, KSB Group, and Sulzer AG compete through engineering depth and regional strength, while firms such as Xylem Inc., ITT Corporation, and IDEX Corporation focus on differentiated capabilities in specialized configurations, smart monitoring, and energy performance.Regional
More news about: Future Market Insights
Feb 17, 2026, 07:00 ET Tencarva Machinery Company, Backed by Bessemer Investors, Acquires Hoffman-Kane Distributors, Inc.
Tencarva secured exclusive territorial rights for two leading OEM partners, expanding their sales region for John Crane into the Ohio Valley and adding ITT Goulds within Hoffman-Kane's territory.Founded in 1962 and based in based in Pittsburgh, PA, Hoffman-Kane offers a broad range of products and
More news about: Bessemer Investors
Feb 17, 2026, 06:00 ET IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
readout have been confirmed by blinded independent central review (BICR);Randomized PFS analysis will be based on the intent-to-treat population (ITT) enrolled in the Phase 2b/3 portion of the trial, which comprises a total of approximately 313 patients randomized 2:1 to the treatment arm versus control;Topline
More news about: IDEAYA Biosciences, Inc.
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
and, 2) the trial's original intent to treat (ITT) population, which includes all patients enrolled in the trial whose tumors are TP53 wild-type, regardless of MMR status. The key secondary endpoint of overall survival will be evaluated in the ITT population. The mITT population is expected to
More news about: Karyopharm Therapeutics Inc.
Feb 10, 2026, 17:31 ET PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight
fulvestrant, exceeding the pre-specified target Hazard Ratio (HR) of 0.60. However, the trial did not reach statistical significance in the intent-to-treat (ITT) population. What are PROTACs?PROTACs (PROteolysis TArgeting Chimeras) are an emerging class of therapeutic molecules designed
More news about: DelveInsight Business Research LLP
Jan 12, 2026, 07:00 ET Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
are medically ineligible for checkpoint inhibitors; b) introduce a new modified intent-to-treat (ITT) population of approximately 220 patients comprised of this focused population; and, c) increase the ITT sample size to approximately 276 patients.Enrollment continues in the
More news about: Karyopharm Therapeutics Inc.
Jan 11, 2026, 12:00 ET IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
UM (mUM) are expected in Q1 '26Randomized PFS analysis is based on the first 130 PFS events from the intent-to-treat population (ITT) enrolled in the Phase 2b/3 portion of the trial, which comprises approximately 313 patients randomized 2:1 to the treatment versus control arm. The
More news about: IDEAYA Biosciences, Inc.
Dec 10, 2025, 04:15 ET Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial.HONG
More news about: Ascletis Pharma Inc.
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
to 78.5% for ibrutinib in the intent-to-treat (ITT) populationProgression-free survival data were immature but trended in favor of pirtobrutinib with a 43% reduction of the risk of disease progression or death in the ITT population, and the treatment-naïve subgroup, which
More news about: Eli Lilly and Company
Nov 10, 2025, 07:30 ET CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE
Google, Microsoft, Yahoo! / AOL, NASA's Advanced Computational Concepts Laboratory, investment banking and private equity, government contracting at ITT & Harris Corporation, and a startup that rapidly scaled by delivering high-performance computing and AI infrastructure worldwide. Collectively, the
More news about: Movano
Nov 05, 2025, 10:57 ET Late-Breaking Clinical Trial Results Announced at VIVA 2025
deliver dual neuroprotection while streamlining procedural steps. A total of 146 patients were enrolled in the pivotal cohort across 26 sites. ITT analysis included 145 evaluable patients (mean age 70.5 years, 21% symptomatic, 39.7% diabetic). Nearly half (49.32%) of patients met anatomic high-risk
More news about: The VIVA Foundation
Nov 03, 2025, 15:30 ET E2 (Endovascular Engineering, Inc) Presents ENGULF Pivotal Study as a Late-Breaking Clinical Trial at the VIVA Conference
interventional cardiology, interventional radiology, and vascular surgery specialties at 19 leading U.S. hospitals. A total of 105 patients were enrolled in the ITT population with a median of two cases per operator. The study met both its primary safety and efficacy endpoints by a wide margin, demonstrating a 0.95%
More news about: Endovascular Engineering, Inc.
Nov 03, 2025, 07:00 ET Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
deficient mismatch repair status (dMMR), who are medically ineligible to receive checkpoint inhibitors; and, 2) the trial's original intent to treat (ITT) population, which will include all patients enrolled in the trial whose tumors are TP53 wild-type, regardless of MMR status. The mITT population is
More news about: Karyopharm Therapeutics Inc.
Oct 31, 2025, 16:15 ET Mary Laschinger Elected to Stanley Black & Decker Board of Directors
Kimberly-Clark Corporation, and Shopko Corporation (Department Store). Laschinger currently serves on the Board of Directors of ITT, a diversified manufacturer of highly engineered critical components and customized technology solutions for the transportation, industrial and energy
More news about: Stanley Black and Decker-Corporate
Oct 22, 2025, 11:10 ET Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
the causative pathogen in ~38% of both the AP-SA02 and placebo groups. Clinical response was assessed in the intent-to-treat (ITT) population at Test of Cure ("TOC") on day 12, one week post-BAT, and End of Study ("EOS") four weeks after BAT completion. Safety analysis also included
More news about: Armata Pharmaceuticals, Inc.
Oct 19, 2025, 11:42 ET Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
methodology. COMPASSION-15 2025 ESMO Data In the intent-to-treat (ITT) population: With long-term follow-up, the cadonilimab regimen demonstrated a significant
More news about: Akeso, Inc.
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
than 75% of patients having been followed for at least four years after completion of the two-year Verzenio treatment period. In the intent-to-treat (ITT) population, Verzenio plus ET reduced the risk of death by 15.8% compared to ET alone [7-year overall survival (OS) rate: 86.8% vs. 85.0%; hazard ratio
More news about: Eli Lilly and Company
Oct 14, 2025, 06:00 ET 歌禮與中國國家藥品監督管理局完成地尼法司他（ASC40）的新藥上市申請前溝通
）達到所有主要、關鍵次要及次要療效終點（意向治療集（ ITT ）分析），與安慰劑相比顯著改善中重度尋常性痤瘡。
More news about: 歌禮製藥有限公司
Oct 14, 2025, 06:00 ET Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled,
More news about: Ascletis Pharma Inc.
Oct 08, 2025, 07:00 ET Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
deficient mismatch repair status (dMMR), who are medically ineligible to receive checkpoint inhibitors; and, 2) the trial's original intent to treat (ITT) population, which will include all patients enrolled in the trial whose tumors are TP53 wild-type, regardless of MMR status. The mITT population is
More news about: Karyopharm Therapeutics Inc.
Oct 06, 2025, 08:00 ET RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
in the Talicia pivotal trial 8 Defined as the PK population which included those subjects in the ITT population who had demonstrated presence of any component of investigational drug at visit 3 (approx. day 13) or had undetected levels drawn >250
More news about: RedHill Biopharma Ltd.